<DOC>
	<DOCNO>NCT01617551</DOCNO>
	<brief_summary>Catheter base renal denervation ( CRD ) humans represent promise new treatment resistant hypertension . CRD currently investigate treatment option patient resistant hypertension define least 3 antihypertensive drug ( include diuretic ) randomize , sham-controlled , multicenter trial Denmark ( ReSet ) . In ReSet , patient randomize either CRD sham procedure 6 month follow . The mechanisms CRD reduce blood pressure partly understood interaction renal sympathetic nerve nitric oxide ( NO ) investigate human . To Study interaction NO renal sympathetic nerve , design present substudy , effect NO-inhibition renal , hemodynamic hormonal variable study CRD .</brief_summary>
	<brief_title>Effect Renal Denervation NO-mediated Sodium Excretion Plasma Levels Vasoactive Hormones</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>omega-N-Methylarginine</mesh_term>
	<criteria>Age 3070 year Stable antihypertensive treatment 1month least 3 antihypertensive drug include diuretic Daytime ambulatory blood pressure &gt; 145/75 mmHg Non compliance Pregnancy/noanticonception fertile woman Radiocontrast allergy Malignancy Congestive heart failure ( EF &lt; 50 ) eGFR &lt; 45 Unstable angina pectoris Recent myocardial infarction PCI ( &lt; 6 mdr ) Secondary hypertension Renal artery stenosis multiple renal artery CT Claudication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Nitric oxide</keyword>
	<keyword>Renal denervation</keyword>
	<keyword>Sodium</keyword>
	<keyword>GFR</keyword>
</DOC>